Levosert

Levonorgestrel, the active ingredient in Levosert, is a progestogen presented as an intrauterine system (IUS) for intrauterine use. The device releases levonorgestrel locally over several years to provide reliable, reversible contraception for women of reproductive age.

GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including both public and private healthcare providers.

Levosert, containing levonorgestrel, is used within the hormonal contraceptive pathway for long‑acting reversible contraception.

Contraception: provides highly effective, reversible birth control for up to five years. Long‑acting reversible contraception (LARC): offers a low‑maintenance option that does not require daily dosing. Prevention of unintended pregnancy: reduces the risk of pregnancy in women seeking a dependable method.

Levosert may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Menstrual cramps or pelvic discomfort - Headache - Breast tenderness or enlargement - Mood changes

Serious or Rare Side Effects: - Pelvic inflammatory disease (PID) - Uterine perforation during insertion - Ectopic pregnancy if contraception fails - Severe allergic reaction (anaphylaxis) - Device expulsion or migration

Before insertion and during use, certain precautions should be observed to ensure safety and effectiveness.

Screening: confirm the patient is not pregnant and has no active pelvic infection. Medical history: assess for contraindications such as unexplained vaginal bleeding, uterine anomalies, or hormone‑sensitive cancers. Follow‑up: schedule a post‑insertion visit to verify correct placement and address any concerns. Bleeding patterns: counsel users about possible changes in menstrual flow, including prolonged spotting. Interaction with hormonal therapies: avoid concurrent systemic estrogen therapy unless medically indicated. Store at ambient temperature: keep the device in its original packaging, protect from moisture and direct sunlight.

Levosert may interact with other medicines that affect hormone metabolism or uterine environment.

Major Interactions (Avoid): - Concurrent systemic estrogen therapy: may increase the risk of thromboembolic events. - Recent uterine surgery (within 6 weeks): raises the chance of device displacement or perforation.

Moderate Interactions (Monitor Closely): - Rifampin, griseofulvin, or other enzyme‑inducing antibiotics: can lower levonorgestrel levels. - Anticonvulsants such as carbamazepine or phenytoin: may reduce contraceptive efficacy. - St. John’s wort or other herbal inducers: possible decreased hormonal effect.